COVID-19 у детей и подростков с муковисцидозом

Abstract

Patients with cystic fibrosis (CF) are a risk group for a severe course of respiratory viral diseases. In this regard, the European Cystic Fibrosis Society has developed the ECFS-COVID-19 surveillance program to collect information on the characteristics of COVID-19 in patients with cystic fibrosis, aimed at providing them with the necessary medical care. This article presents part of a study of Russian patients. Objective. To assess the prevalence and course of COVID-19 in Russian patients with CF and in the general Russian population. Materials and methods. From the beginning of the pandemic to December 31, 2020, 35 cases of COVID-19 in Russian children and adolescents with CF and 347,749 cases in the general population of children and adolescents were analyzed (findings from the Central Research Institute of Epidemiology of Rospotrebnadzor). Results. The proportion of children with COVID-19 in the Russian Federation was 11.3% of all reported cases, and the proportion of CF patients with COVID-19 – 10.1 per 1,000 pediatric CF patients. The main symptoms of COVID-19 in children with CF were fever, cough, rhinorrhea, abdominal pain syndrome, and no loss of smell. Most CF patients had asymptomatic or mild form of COVID-19, and hospitalization was more frequent compared to the general pediatric population. Conclusion. The study resulted in determination of prevalence of SARS-CoV-2 in CF patients and its clinical characteristics. Key words: cystic fibrosis, COVID-19, morbidity, pneumonia, antibacterial therapy